

# CITATION REPORT

List of articles citing

The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation

DOI: 10.1016/s1665-2681(19)31798-3  
Annals of Hepatology, 2009, 8, 158-161.

**Source:** <https://exaly.com/paper-pdf/45361071/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Emphasizing the importance of the clinical classification for pulmonary hypertension. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 267-268	3.1	5
16	Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2297-313	4	12
15	Pulmonary complications in cirrhosis. <i>Current Opinion in Organ Transplantation</i> , <b>2011</b> , 16, 281-8	2.5	20
14	Trends on gastrointestinal bleeding and mortality: where are we standing?. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 1154-8	5.6	51
13	Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. <i>Liver Transplantation</i> , <b>2012</b> , 18, 686-95	4.5	70
12	Portopulmonary hypertension: an update. <i>Liver Transplantation</i> , <b>2012</b> , 18, 881-91	4.5	73
11	Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. <i>Liver International</i> , <b>2015</b> , 35, 1646-60	7.9	57
10	Appraising cardiac dysfunction in liver transplantation: an ongoing challenge. <i>Liver International</i> , <b>2015</b> , 35, 12-29	7.9	22
9	International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. <i>Transplantation</i> , <b>2016</b> , 100, 1440-52	1.8	188
8	Pharmacologic Issues in Liver Disease. <i>Critical Care Clinics</i> , <b>2016</b> , 32, 397-410	4.5	8
7	Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 301-307	3.3	13
6	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , <b>2017</b> , 65, 1683-1692	11.2	40
5	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , <b>2017</b> , 8, 99179-99202	3.3	28
4	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 406-460	13.4	930
3	Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report. <i>Surgical Case Reports</i> , <b>2018</b> , 4, 15	0.8	1
2	Cardiopulmonary Complications of Cirrhosis. <b>2018</b> , 281-292.e5		
1	ISHLT CONSENSUS STATEMENT: Peri-operative Management of Patients with Pulmonary Hypertension and Right Heart Failure Undergoing Surgery. <i>Journal of Heart and Lung Transplantation</i> , <b>2022</b> ,	5.8	0

